Adocia | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,588.00
704.00
36,936.00
22,488.00
19,469.00
47,389
Cost of Goods Sold (COGS) incl. D&A
1,922.00
2,907.00
6,377.00
8,018.00
35,135.00
43,663
Gross Income
3,666.00
2,203.00
30,559.00
14,470.00
15,666.00
3,726
EBIT
7,536.00
20,620.00
2,286.00
-
15,888.00
3,167
Non Operating Income/Expense
34.00
3,446.00
7,423.00
7,578.00
130.00
713
Interest Expense
107.00
71.00
37.00
78.00
110.00
149
Pretax Income
7,508.00
16,637.00
12,220.00
7,821.00
16,050.00
5,390
Income Tax
3,215.00
4,078.00
333.00
71.00
7,500.00
2,225
Consolidated Net Income
4,293.00
20,715.00
12,553.00
7,892.00
8,550.00
7,615
Net Income
4,293.00
20,715.00
12,553.00
7,892.00
8,550.00
7,615
Net Income After Extraordinaries
4,293.00
20,715.00
12,553.00
7,892.00
8,550.00
7,615
Net Income Available to Common
4,293.00
20,715.00
12,553.00
7,892.00
8,550.00
7,615
EPS (Basic)
0.70
3.30
1.90
1.20
1.20
1.10
Basic Shares Outstanding
6,206.00
6,213.10
6,689.20
6,847.40
6,863.50
6,916.30
EPS (Diluted)
0.69
3.33
1.80
1.15
1.25
1
Diluted Shares Outstanding
6,206.00
6,213.10
6,973.90
6,847.40
6,863.50
7,615
EBITDA
7,176.00
20,223.00
2,754.00
15,204.00
14,880.00
4,205
Other Operating Expense
11,202.00
18,417.00
28,273.00
30,437.00
222.00
559
Non-Operating Interest Income
169.00
608.00
2,548.00
646.00
78.00
1,659

About Adocia

View Profile
Address
115 avenue Lacassagne
Lyon Rhone-Alpes 69003
France
Employees -
Website http://www.adocia.com
Updated 07/08/2019
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: BioChaperone Lispro; BioChaperone Combo; HinsBet; BioChaperone Human Glucagon; BioChaperone Glargine GLP-1; and BioChaperone Prandaial Combinations for T1D. The company was founded by Gérard, Olivier, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.